Lupinac Tablet is a combination pharmaceutical formulation containing Taurine 500 mg and Acetylcysteine 150 mg, designed to provide synergistic therapeutic benefits primarily in the management of respiratory and hepatic conditions. Taurine, a sulfur-containing amino acid, plays a critical role in cellular osmoregulation, antioxidant defense, and membrane stabilization, contributing to improved cellular function and protection against oxidative stress. Acetylcysteine, a well-established mucolytic agent, acts by breaking disulfide bonds in mucus glycoproteins, thereby reducing mucus viscosity and facilitating expectoration. Additionally, Acetylcysteine serves as a precursor to glutathione, a vital intracellular antioxidant, enhancing detoxification processes and mitigating oxidative damage in hepatic tissues. Lupinac Tablet is indicated for patients with chronic respiratory diseases characterized by excessive or thickened mucus secretions, such as chronic bronchitis, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, as well as for the adjunctive treatment of hepatic disorders where oxidative stress is implicated. The combined action of Taurine and Acetylcysteine supports improved respiratory function and hepatic protection by reducing inflammation, oxidative injury, and mucus accumulation. Lupinac should be administered under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Common adverse effects may include gastrointestinal discomfort and hypersensitivity reactions, warranting careful monitoring during therapy.